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Abstract 
Background: To assess the activity of Indoleamine 
2, 3 Dioxygenase (IDO) in Type 2 Diabetes Mellitus 
Patients in Pakistan 
Methods:  In this prospective study, activity and 
expression of IDO , was assessed in sera of diabetics and 
healthy controls (n=28). Colorimetric Assay was 
performed to analyze IDO activity in samples.   
Results: A significant difference was observed  
between the means of control and diabetic patients 
with a p-value of 0.0001.  
Conclusion: IDO concentrations were significantly 
higher in the serum of samples of diabetes mellitus 
patients as compared to control .  
Key words: Diabetes Mellitus, Indoleamine 2, 3 
dioxygenase, kynurenine pathway 
 
Introduction 
Indoleamine 2, 3 dioxygenase, an intracellular enzyme, 
regulates the degradation of L-tryptophan through 
kynurenine pathway. Upon induction of IFN-γ, dendritic 
cells (DCs), macrophages, fibroblasts and endothelial cells 
specify IDO protein. Specific immune systems are 
modulated by IDO in the course of various inflammatory 
and autoimmune diseases.  Diabetics with over expression of 
IDO are susceptible to various bacterial, viral and fungal 
infections. Diabetes mellitus is a worldwide issue, 
responsible for effecting approximately 381 million 
individuals. According to WHO, 7 million people are 
affected by diabetes in Pakistan in 2012.   Diabetes 
characterized by hyperglycemia, is a group of metabolic 
diseases resulting from irregularity in secretion or action of 
insulin or both. Long-term damage, irregular function and 
organ failure specifically the kidneys, nerves, eyes, heart and 
blood vessels are involved in chronic hyperglycemia of 
diabetes. 
1
 Diabetics are found to be more susceptible to 
certain bacterial, viral and fungal infections and have 
enhanced prevalence of cardiovascular, atherosclerotic, 
cerebrovascular disease and peripheral arterial. 
2
 
There are two classes of Diabetes Mellitus i.e.  Type 1 
and Type 2 of which Type 2 constitutes 90% of the 
cases. According to the World Health Organization 
(WHO), in 2015, approximately 422 million 
individuals were affected with diabetes. Prevalence is 
rapidly increasing and this number is determined to 
almost double by 2030. According to World Health 
Organization (WHO), in Pakistan, Seven million 
people are affected with diabetes mellitus, both types. 
Currently, Diabetes Mellitus is incurable, but 
depending on the type of diabetes suffered by the 
individual it can be managed. The goal for the 
treatment of diabetes is controlling blood glucose 
levels, in turn to prevent disease complications. 
Indoleamine 2, 3 dioxygenase (IDO), heme containing 
enzyme, regulate catalytic degradation of tryptophan.3 
IDO is involved in the modulation and 
downregulation of immune system by tryptophan 
degradation.4 Tryptophan, an essential amino acid 
(AA) and is vital for all living organisms and required 
in various metabolic pathways. Degradation of 
tryptophan results in the production of kynurenines 
leading to the suppression of cell proliferation. 
Immunomodulatory effects are produced in the 
biological systems 5. IDO is involved in progression of 
several inflammatory reactions occurring in major 
diseases ranging from cancer, autoimmunity, infection 
and allergic reactions.4 
Immunology of IDO is complex in nature. According 
to current knowledge, activity of IDO directly affects 
T-cells. Apoptosis is induced by IDO either through 
depletion of tryptophan or through tryptophan 
metabolites. The first mechanism discovered for IDO 
activity was tryptophan depletion. Induction of IDO 
is predominantly triggered by macrophages and 
dendritic cells. During inflammation, IDO is 
significantly upregulated by Interferon gamma (IFN-
γ), which in turn is extremely fundamental for the 
development of T-cell and initiation of inflammatory 
response against infections and diseases. Enzymatic 
activity of IDO is indicated by the rate of tryptophan 
degradation and the ratio of kynurenine to 
tryptophan (Kyn/Trp) can be used as an indicator for 
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degradation of tryptophan as well as in the activation 
of immune system. 6 
Many inhibitors of IDO are being studied but 1-
methyl tryptophan (1MT) has been considered as a 
potent inhibitor of enzymatic activity of IDO.3 1MT 
has favorable pharmacokinetic characteristics such as 
oral availability, low protein binding and low 
clearance.7 IDO is involved in the progression of 
numerous pathological conditions ranging from 
various cancers, infections, allergies and autoimmune 
diseases. IDO and its differential response have been 
studied in several systems.  
Current study focuses on the assessment of activity of 
indoleamine 2, 3 dioxygenase in diabetes mellitus 
type 2. According to a WHO survey in 2014, global 
prevalence of prevalence of diabetes was estimated to 
be 9% among adults aged 18 and above years. In 
Pakistan, approximately 7 million individuals are 
affected by diabetes. IDO has never been studied 
previously in relation to diabetes mellitus type 2.  
 
Patients and  Methods 
Total 89 blood samples were collected from which 61 
were diabetic samples while 28 were control samples. 
Serum was extracted from blood samples through 
centrifugation at 14000 rpm for 5-7 minutes. Extracted 
samples were stored at -80 degree C. For colorimetric 
assay of Kynurenine two solutions namely Solution A 
and Solution B were prepared . Solution A was 30% 
trichloro-acetic acid (TCA) solution in glacial acetic 
acid while Solution B was 20% Ehlrich reagent (p-
dimethylbenzaldehyde) in glacial acetic acid. The 
function of TCA is to precipitate proteins in sample 
and Ehlrich reagent imparts color which binds to IDO.  
200μL of serum sample was added from diabetic 
patient as well as from healthy control in an 
Eppendorf tube. They were labelled on the basis of 
their well number.100μL of solution A was addedin 
the samples. This process was repeated for all the 
samples separately. The mixture was then centrifuged 
at 14000 rpm for 3 minutes. After centrifugation two 
separate layers are established. 125μL of supernatant 
was added  from each 96 Eppendorf tube to a separate 
well of 96-well plate. After all the wells were filled and 
125μL of solution B  was added which resulted in an 
immediate change of colour. This change in colour was 
assessed through Dynex Technologies microplate 
reader by measuring the absorbance of light at 490nm. 
IDO activity corroborated in diabetic samples as well 
as control samples through kynurenine concentration 
absorbance procured from microplate reader. Different 
concentrations of kynurenine were checked for 
absorbance at 490nm and a standard curve was 
established in 96-well plate by conducting colorimetric 
assay (Figure 1).  
  
 
Figure 1: Kynurenine standard curve 
 
Results 
 
Enzymatic activity of IDO, due to the incongruity 
between IDO expression and activity. Six diabetics had 
hypertension (Table 1). A significant difference was 
observed between the means of control and diabetic 
patients with a p-value of 0.0001 (Table 2).  Unpaired 
T-test was applied and it revealed significant up 
regulation in IDO expression with a p-value of 0.0095.  
 
Table 1: Diabetics and controls- Demographic 
and clinical profile 
Characteristics Diabetic 
Samples  
(n=61) 
Control  
Samples  
(n=28) 
Age 58 (43-84) 33 (21-40) 
Sex (M/F) 25/36 14/14 
Hypertension (Y/N) 6/55 0/28 
Cardiac Complications 6/55 0/28 
Viral Infections (Y/N) 0/61 0/28 
 
Table 2: IDO activity in diabetics and controls 
IDO activity in samples  
Patients Diabetic 
samples (n=61) 
Control 
samples 
(n=28) 
p-value 
Kynurenine Conc. 
 Absorbance 
Average 
0.2521 0.0545 0.0001 
Discussion 
According to the World Health Organization (WHO), 
in 2015, approximately 422 million individuals were 
affected with diabetes. Prevalence is rapidly increasing 
and this number is determined to almost double by 
2030. According to World Health Organization 
(WHO), in Pakistan, Seven  million people are affected 
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with diabetes mellitus, both types. Being an 
underdeveloped country, Pakistan allots minimal 
quota for the health budget, 24 dollars per person cost 
of diabetes in Pakistan.  IDO is involved in the up 
regulation of IFN-γ in diabetic patients and up 
regulates production through human islets cells. 8 
In this study, we established a correlation between up 
regulation of IDO and Diabetes Mellitus. We evaluated 
the enzymatic activity of IDO in serum of diabetes 
mellitus patients. A marked higher expression and 
activity of IDO was observed in diabetes mellitus 
patients as compared to healthy controls.  
Indoleamine 2, 3 dioxygenase (IDO), heme containing 
enzyme, regulate catalytic degradation of tryptophan, 
an essential amino acid 3. It has vital role in 
metabolism of tryptophan and performs cleavage in 
indole ring of a double bond at 2, 3 positions, 
consequently is also the rate limiting step of this 
catabolic pathway 3. IDO is expressed in varying 
amounts by numerous tissues along with antigen 
presenting cells (APCs). It is intracellular in nature, 
extracellular form has not been reported yet. Activity 
and expression of IDO has been evident in trophoblast 
cells at fetal-maternal interface. 9  
Lately, a new enzyme has been reported having 
similar activity to IDO 10.  The enzyme is cited as 
indoleamine 2, 3 dioxygenase-2 (also proto 
indoleamine 2, 3-dioxygenase or indoleamine 2, 3-
dioxygenase like protein) because of its structural and 
functional analogy with IDO. IDO is a monogenic 
protein and has 15 kb gene, constituted of 10 exons, 
present in chromosome 8 at the syntenic region in mice 
as well as humans. IDO is reported to be well 
conserved. 11IDO gene transcription is strictly 
regulated and is prevalent in a limited number of cells. 
Only specific set inflammatory and genetic promoters 
can upregulate IDO transcription. Various pro-
inflammatory promoters are strong inducers of IDO 
like type II interferons (IFN-γ) in turn type I 
interferons (IFN-α and IFN-β) are less potent 
inducers.12 IDO protein is specifically expressed by 
macrophages, endothelial cells, fibroblasts and 
dendritic cells (DCs) upon the induction by IFN-γ. 9 
STAT-1 and IRF1 along with IFN-γ are involved in 
the IDO induction 13. IFN-γ is strongly associated 
with inflammation and IDO induction; consequently 
various others potent inducers are also present to 
induce IDO expression along with IFN-γ. Tumor 
Necrosis Factors (TNF) and lipopolysaccharide (LPS) 
are potent inducers.14 Absence of IFN-γ is unaffected 
in the induction of IDO through LPS, although LPS 
requires TNF to support its responsiveness 15 which 
reiterates metabolic pathways of IDO induction 
independent of IFN-γ present. Complex transcription 
and expression is enhanced by certain cell specific 
cytokines. 
Tryptophan, an essential amino acid (AA) and is vital 
for all living organisms and required in various 
metabolic pathways. Animals are unable to produce 
tryptophan by themselves and hence are dependent 
on primary producers for the flow of tryptophan.       
From the digestive system, tryptophan is taken to the 
liver where it is utilized in various ways:Biosynthesis 
of Serotonin, Protein Synthesis and Kynurenine 
degradation pathway .Various biological mechanisms 
are affected; kynurenine pathway metabolizes most 
of the tryptophan. It is imperative in the production 
of serotonin. Degradation of tryptophan results in the 
production of kynurenines leading to the suppression 
of cell proliferation. 5  In tryptophan catabolism, two 
important enzymes are involved , e.g., Indoleamine 2, 
3-doioxygenase (IDO) and Tryptophan 2, 3-
dioxygenase (TDO).Tryptophan and certain 
metabolic steroids activate the enzyme.16 
 IFN-γ is the potent inducer of IDO and is expressed 
in several tissues. 17 Activated T-cells secrete IFN-γ as 
well as other leukocytes having the ability for the 
induction of reactive nitrogen species (RNS) and 
reactive oxygen species (ROS) in macrophages  and 
neutrophils. 18,19 Inexplicable role of IFN-γ during an 
immune response is well documented during 
vigorous and sustained catabolism of tryptophan. 20  
Although the biological significance of IFN-γ 
mediated degradation of tryptophan is not 
completely comprehended, researchers believe that it 
is linked in prevention of tryptophan supply to 
intracellular parasites, cancer cells and pathogens.21 
In recent years, these roles have gained attention. 
Immunology of IDO is complex in nature. In specific 
cases, IDO can proliferate the pathogen growth or be 
beneficial to any disease inflicting factor thus in turn 
damaging the host. In tissues, generation of 
immunosuppressive microenvironment is a matter of 
extensive research. According to current knowledge, 
activity of IDO directly affects T-cells. Apoptosis is 
induced by IDO either through depletion of 
tryptophan or through tryptophan metabolites. The 
first mechanism discovered for IDO activity was 
tryptophan depletion. On the other hand, 
antimicrobial effects of IDO are reversed by the 
addition of tryptophan. Inhibition of T-cells was 
observed to be reversed through numerous studies 
conducted by different researchers. 22   
T-cells are detrimentally effected by metabolites 
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produced by the degradation of tryptophan through 
IDO i.e. 3-hydroxyanthranilic acid and quinolinic 
acid even if externally added. It is hypothesized that 
the metabolites bind to the receptors and either block 
or be directly toxic to the cells. T-cell affinity 
determined by molecular pathways to metabolites of 
IDO is yet to be studied. However, specific pathways 
such as activation of GCN2 kinase pathway by amino 
acid withdrawal and inhibition of mTOR 
(mammalian target of rapamycin) pathway are 
known.  
Through advancement in knowledge of biological 
effects of IDO and computer mediated drug design 
strategies, study and synthesis of inhibitors of IDO 
has got attention from numerous researchers. 
Competitive and Non-competitive IDO inhibitors 
have been studied along with competitive inhibitors 
constituted  from tryptophan derivatives and non-
competitive inhibitors derived from  βarboline. 23 
1-methyl tryptophan (1MT) is the most widely 
studied inhibitor of IDO. 1MT has favourable 
pharmacokinetic characteristics such as oral 
availability, low protein binding and low clearance 24. 
Methyl-thiohydantoin-L-tryptophan (MTH-Trp) was 
found be much potent inhibitor than 1MT during 
screening for IDO inhibitors of competitive nature. 25  
In different pathological conditions, IDO has 
numerous roles in human beings. Enhanced activity of 
IDO has been reported in various tumors in their 
microenvironment 26 resulting in T-cell suppression. 
Poor prognosis of cancer is associated with IDO  and 
elevated levels of kynurenine have been reported in 
patient samples. 27,28  
 
Conclusion 
1. Enzymatic activity of IDO measured through 
colorimetric assay indicates that IDO might be 
involved in progressing the symptoms and 
susceptibility to infections in diabetes mellitus 
patients.  
2.Blocking IDO or inhibiting its production can 
provide new strategies as an advent  intervention 
therapy for diabetes mellitus 
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